Medifast, Inc.

NYSE:MED 주식 보고서

시가총액: US$196.1m

Medifast 과거 수익 실적

과거 기준 확인 0/6

Medifast의 수입은 연평균 -3.2%의 비율로 감소해 온 반면, Personal Products 산업은 수입이 연평균 9.3%의 비율로 증가했습니다. 매출은 연평균 5.3%의 비율로 증가해 왔습니다. Medifast의 자기자본이익률은 3.5%이고 순이익률은 1.1%입니다.

주요 정보

-3.2%

수익 성장률

-1.7%

EPS 성장률

Personal Products 산업 성장20.9%
매출 성장률5.3%
자기자본 수익률3.5%
순이익1.1%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

Recent updates

Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued

Nov 06

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

Sep 03

Medifast Business Continues To Shrink, Stock Still Risky

Aug 27

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Jun 26

Medifast: Significant Undervaluation Even As Struggles Persist

May 24

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

Medifast: Cheap Valuation, Uncertain Future

Mar 20

Medifast Is Getting Attractive

Mar 07

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26
Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05
Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19
At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Medifast declares $1.64 dividend

Dec 08

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Dec 01
A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 10
Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Nov 08
One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy

Nov 06

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Oct 20
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Sep 18
We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Medifast declares $1.64 dividend

Sep 08

Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Sep 02
Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Aug 21

수익 및 비용 분석

Medifast 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NYSE:MED 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 2467474705
30 Jun 24770295315
31 Mar 24898685705
31 Dec 231,072996455
30 Sep 231,2181207135
30 Jun 231,3731337964
31 Mar 231,5301428975
31 Dec 221,5991449515
30 Sep 221,6391519824
30 Jun 221,6621579994
31 Mar 221,6031659594
31 Dec 211,5261649074
30 Sep 211,4131588374
30 Jun 211,2711507454
31 Mar 211,0971256443
31 Dec 209351035613
30 Sep 20841955093
30 Jun 20759764723
31 Mar 20726764553
31 Dec 19714784433
30 Sep 19689744232
30 Jun 19638723902
31 Mar 19568643492
31 Dec 18501563092
30 Sep 18433472692
30 Jun 18371402282
31 Mar 18330342022
31 Dec 17302281880
30 Sep 17286251772
30 Jun 17277241732
31 Mar 17273201682
31 Dec 16275181702
30 Sep 16273181673
30 Jun 16271171663
31 Mar 16272191692
31 Dec 15273201692
30 Sep 15274181670
30 Jun 15277181700
31 Mar 15279191710
31 Dec 14285211731
30 Sep 14267271570
30 Jun 14285271700
31 Mar 14307281870
31 Dec 13324272020

양질의 수익: MED 에는 $12.5M 큰 일회성 손실이 있습니다. $12.5M 은 지난 12개월 간의 재무 결과에 30th September, 2024 까지 영향을 미쳤습니다.

이익 마진 증가: MED 의 현재 순이익 이익률 (1.1%) 작년보다 낮습니다 (9.8%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: MED 의 수입은 지난 5년 동안 매년 3.2% 씩 감소했습니다.

성장 가속화: MED 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: MED 은 지난 1년 동안 마이너스 수익 성장( -93.9% )을 기록하여 Personal Products 업계 평균( -5.2% ).

자기자본 수익률

높은 ROE: MED 의 자본 수익률( 3.5% )은 낮음으로 간주됩니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

7D

1Y

7D

1Y

7D

1Y